You are here

Lava Therapeutics

Lava, smoldering from dropping lead asset, lays off 30% of staff to save cash

Fierce Biotech

Tue, 02/25/25 - 10:52 am

Lava Therapeutics

Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup

Fierce Biotech

Tue, 12/10/24 - 11:32 am

Lava Therapeutics

clinical trials

prostate cancer

Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

BioPharma Dive

Mon, 09/26/22 - 11:20 pm

Lava Therapeutics

bispecific antibodies